259 related articles for article (PubMed ID: 32593312)
1. Patterns of recurrence in adenocarcinoma of the esophagogastric junction: a retrospective study.
Xu H; Zhang L; Miao J; Liu S; Liu H; Jia T; Zhang Q
World J Surg Oncol; 2020 Jun; 18(1):144. PubMed ID: 32593312
[TBL] [Abstract][Full Text] [Related]
2. [Survival comparison of Siewert II adenocarcinoma of esophagogastric junction between transthoracic and transabdominal approaches:a joint data analysis of thoracic and gastrointestinal surgery].
Yang S; Yuan Y; Hu H; Li R; Liu K; Zhang W; Yang K; Yang Y; Bai D; Chen X; Zhou Z; Chen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb; 22(2):132-142. PubMed ID: 30799535
[TBL] [Abstract][Full Text] [Related]
3. [Effects of robotic and laparoscopic-assisted surgery on lymph node dissection and short-term outcomes in patients with Siewert II adenocarcinoma of esophagogastric junction].
Wang D; Cao S; Tan X; Liu S; Liu X; Niu Z; Chen D; Wang D; Zhang J; Lv L; Li Y; Jiang H; Guo D; Li Y; Li Z; Zhou Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb; 22(2):156-163. PubMed ID: 30799538
[TBL] [Abstract][Full Text] [Related]
4. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
[No Abstract] [Full Text] [Related]
5. Mediastinal lymph node dissection and distal esophagectomy is not essential in early esophagogastric junction adenocarcinoma.
Lee IS; Ahn JY; Yook JH; Kim BS
World J Surg Oncol; 2017 Jan; 15(1):28. PubMed ID: 28100248
[TBL] [Abstract][Full Text] [Related]
6. Adenocarcinomas of the esophagogastric junction: experiences at a single institution in China.
Zhang H; Wang W; Cheng Y; Song Y; Zhu K; Dang C
World J Surg Oncol; 2013 Jul; 11():155. PubMed ID: 23849250
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological features and prognostic factors of adenocarcinoma of the esophagogastric junction according to Siewert classification: experiences at a single institution in Japan.
Hosokawa Y; Kinoshita T; Konishi M; Takahashi S; Gotohda N; Kato Y; Daiko H; Nishimura M; Katsumata K; Sugiyama Y; Kinoshita T
Ann Surg Oncol; 2012 Feb; 19(2):677-83. PubMed ID: 21822549
[TBL] [Abstract][Full Text] [Related]
8. [Effect of number of metastatic lymph nodes and metastatic lymph node ratio on the prognosis in patients with adenocarcinoma of the esophagogastric junction after curative resection].
Zhang H; Chen C; Yue J; Ma M; Ma Z; Yu Z
Zhonghua Zhong Liu Za Zhi; 2014 Feb; 36(2):141-6. PubMed ID: 24796465
[TBL] [Abstract][Full Text] [Related]
9. Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours.
Thomaschewski M; Hummel R; Petrova E; Knief J; Wellner UF; Keck T; Bausch D
World J Gastroenterol; 2018 Apr; 24(13):1429-1439. PubMed ID: 29632424
[TBL] [Abstract][Full Text] [Related]
10. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach?
Heger U; Blank S; Wiecha C; Langer R; Weichert W; Lordick F; Bruckner T; Dobritz M; Burian M; Springfeld C; Grenacher L; Siewert JR; Büchler M; Ott K
Ann Surg Oncol; 2014 May; 21(5):1739-48. PubMed ID: 24419755
[TBL] [Abstract][Full Text] [Related]
11. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry.
Münch S; Habermehl D; Agha A; Belka C; Combs SE; Eckel R; Friess H; Gerbes A; Nüssler NC; Schepp W; Schmid RM; Schmitt W; Schubert-Fritschle G; Weber B; Werner J; Engel J
Strahlenther Onkol; 2018 Feb; 194(2):125-135. PubMed ID: 29071366
[TBL] [Abstract][Full Text] [Related]
12. Adenocarcinomas of the esophagogastric junction are more likely to respond to preoperative chemotherapy than distal gastric cancer.
Reim D; Gertler R; Novotny A; Becker K; zum Büschenfelde CM; Ebert M; Dobritz M; Langer R; Hoefler H; Friess H; Schumacher C
Ann Surg Oncol; 2012 Jul; 19(7):2108-18. PubMed ID: 22130620
[TBL] [Abstract][Full Text] [Related]
13. Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma.
Anderegg MCJ; van der Sluis PC; Ruurda JP; Gisbertz SS; Hulshof MCCM; van Vulpen M; Mohammed NH; van Laarhoven HWM; Wiezer MJ; Los M; van Berge Henegouwen MI; van Hillegersberg R
Ann Surg Oncol; 2017 Aug; 24(8):2282-2290. PubMed ID: 28424936
[TBL] [Abstract][Full Text] [Related]
14. Comparison of preoperative concurrent chemoradiotherapy with chemotherapy alone in patients with locally advanced siewert II and III adenocarcinoma of the esophagogastric junction.
Ge X; Zhao Q; Song Y; Li J; Liu M; Bai W; Qiao X
Eur J Surg Oncol; 2018 Apr; 44(4):502-508. PubMed ID: 29395438
[TBL] [Abstract][Full Text] [Related]
15. Influence of Different Neoadjuvant Chemotherapy Regimens on Response, Prognosis, and Complication Rate in Patients with Esophagogastric Adenocarcinoma.
Springfeld C; Wiecha C; Kunzmann R; Heger U; Weichert W; Langer R; Stange A; Blank S; Sisic L; Schmidt T; Lordick F; Jäger D; Grenacher L; Bruckner T; Büchler MW; Ott K
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S905-14. PubMed ID: 26001861
[TBL] [Abstract][Full Text] [Related]
16. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials.
Oppedijk V; van der Gaast A; van Lanschot JJ; van Hagen P; van Os R; van Rij CM; van der Sangen MJ; Beukema JC; Rütten H; Spruit PH; Reinders JG; Richel DJ; van Berge Henegouwen MI; Hulshof MC
J Clin Oncol; 2014 Feb; 32(5):385-91. PubMed ID: 24419108
[TBL] [Abstract][Full Text] [Related]
17. [Clinical and pathological prognostic factors for cancers of the esophagogastric junction].
Schmidt SC; Schlechtweg N; Veltzke-Schlieker W; Thuss-Patience P; Pratschke J; Neuhaus P; Schumacher G
Zentralbl Chir; 2009 Sep; 134(5):455-61. PubMed ID: 19757346
[TBL] [Abstract][Full Text] [Related]
18. Extranodal metastasis is a powerful prognostic factor in patients with adenocarcinoma of the esophagogastric junction.
Zhang HD; Tang P; Duan XF; Chen CG; Ma Z; Gao YY; Zhang H; Yu ZT
J Surg Oncol; 2013 Dec; 108(8):542-9. PubMed ID: 24018956
[TBL] [Abstract][Full Text] [Related]
19. [Short-term efficacy and safety of the synchronous neoadjuvant chemoradiotherapy with paclitaxel plus carboplatin in stage III adenocarcinoma of esophagogastric junction].
Ji Y; Peng T; Wang G; Zhang Y; Cao M; Gao Q; Li S
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1019-1024. PubMed ID: 30269322
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of the superiority of different TNM staging systems in Siewert III adenocarcinoma of esophagogastric junction].
Lu Y; Xi H; Xie T; Qiu Z; Wang X; Wei B; Chen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb; 22(2):143-148. PubMed ID: 30799536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]